Nonresponder Considerations for Romosozumab Treatment

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Osteoporosis treatment aims to increase bone mineral density (BMD).
• Romosozumab effectively increases BMD, but patient response varies.
• Identifying nonresponders is crucial for optimizing osteoporosis management.

Purpose of the Study:

• To identify risk factors for nonresponse to romosozumab treatment.
• To evaluate the proportion of osteoporosis patients who do not achieve significant BMD increase with romosozumab.
• To determine predictors of romosozumab nonresponse.

Main Methods:

• Retrospective observational study of 92 osteoporosis patients.
• Romosozumab (210 mg) administered subcutaneously every 4 weeks for 12 months.
• Exclusion of patients with prior osteoporosis treatment to isolate romosozumab's effect.
• Comparison of demographics and biochemical markers between responders and nonresponders, defining nonresponse as <3% BMD change after 12 months.

Main Results:

• 11.5% of patients were nonresponders at the lumbar spine; 56.8% at the hip.
• Low type I procollagen N-terminal propeptide (P1NP) levels at 1 month (cutoff 50 ng/ml) were a risk factor for lumbar spine nonresponse.
• Significant BMD improvement was not observed in 11.5% (lumbar spine) and 56.8% (hip) of patients.

Conclusions:

• Early P1NP levels can predict romosozumab treatment response in osteoporosis.
• Clinicians can utilize identified risk factors to guide romosozumab treatment decisions.
• Further research may explore mechanisms behind variable romosozumab efficacy.